J&J(JNJ) Prnewswire·2025-06-03 14:45Core Insights - Johnson & Johnson announced promising initial Phase 1 results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody targeting relapsed or refractory multiple myeloma, showing an overall response rate (ORR) of 86.1% among 36 patients at the recommended phase 2 dose (RP2D) [1][2] - The study highlighted that the ORR was 100% in 27 patients who had not previously received BCMA and GPRC5D directed therapies, indicating strong efficacy in treatment-naive patients [1][2] - JNJ-5322 is designed to bind simultaneously to three targets, aiming to address tumor heterogeneity and resistance, which is a significant advancement over existing bispecific antibodies [1][3] Clinical Trial Details - The Phase 1 study involved 126 heavily pretreated patients with a median follow-up of 8.2 months, with a recommended RP2D of 100 mg administered every four weeks [2] - The trial's findings were presented at the 2025 ASCO Annual Meeting and will also be featured at the 2025 EHA Congress [1] Safety Profile - The most common adverse event reported was cytokine release syndrome (CRS), occurring in 59% of patients, with no Grade 3 or higher events noted [3][4] - Grade 3 or higher infections were reported in 28% of patients, and there were four treatment-emergent deaths, including one related to adenoviral encephalitis [3][4] Industry Context - Multiple myeloma is the second most common blood cancer globally, with over 35,000 new diagnoses expected in the U.S. in 2024, highlighting the need for effective treatment options [5] - The five-year survival rate for multiple myeloma patients is approximately 59.8%, indicating a significant unmet medical need in this area [5] Company Vision - Johnson & Johnson aims to transform oncology outcomes through next-generation immunotherapies, leveraging its portfolio of therapies to provide clinicians with effective treatment options for multiple myeloma [3][6]